Developing Differentiated Medicines 

PureTech is developing medicines for devastating diseases including intractable cancers, lymphatic, GI diseases, CNS disorders, inflammatory and immunological diseases.

Exploring the Brain Immune Gut (BIG) axis

24 product candidates

14 are clinical stage

1 FDA cleared product

Relationships with major pharma companies

Amgen Novartis Lilly Merck Boehringer Ingelheim Bristol-Myers Squibb Janssen Roche

Team of industry leaders and experts

Publications
Publications
Nature Neuroscience: CNS lymphatic drainage and neuroinflammation are regulated by meningeal lymphatic vasculature
Publications
Internal Pipeline
PureTech's Lymphatic Leap
Publications
Gamma Delta T Cells Support Pancreatic Oncogenesis by Restraining αβ T Cell Activation
Press releases
2019-12-10
PureTech Affiliate Vedanta Biosciences Announces Initiation of First-in-Patient Study of Immuno-Oncology Candidate VE800 In Combination with Bristol-Myers Squibb's Opdivo® (Nivolumab)

Continue

Press releases
2019-12-09
PureTech Health Affiliate Gelesis Secures Over $84 Million in New Capital to Support US Commercialisation of PLENITY

Continue

Press releases
2019-12-05
PureTech Affiliate Vedanta Biosciences Awarded $5.8 Million CARB-X Grant to Accelerate Development of VE707 for Multi-Drug Resistant Infections

Continue